CLVT icon

Clarivate

5.36 USD
+0.27
5.30%
At close Jan 21, 4:00 PM EST
After hours
5.36
+0.00
0.00%
1 day
5.30%
5 days
5.51%
1 month
7.63%
3 months
-19.28%
6 months
-18.66%
Year to date
4.08%
1 year
-41.74%
5 years
-72.33%
10 years
-60.24%
 

About: Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.

Employees: 12,000

0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

66% more call options, than puts

Call options by funds: $217K | Put options by funds: $131K

24% more capital invested

Capital invested by funds: $3.63B [Q2] → $4.49B (+$863M) [Q3]

9% more funds holding in top 10

Funds holding in top 10: 11 [Q2] → 12 (+1) [Q3]

0.76% less ownership

Funds ownership: 88.11% [Q2] → 87.35% (-0.76%) [Q3]

1% less repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 67

3% less funds holding

Funds holding: 206 [Q2] → 199 (-7) [Q3]

11% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 36

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$4
25%
downside
Avg. target
$5
7%
downside
High target
$6
12%
upside

2 analyst ratings

positive
0%
neutral
50%
negative
50%
RBC Capital
Ashish Sabadra
69% 1-year accuracy
40 / 58 met price target
12%upside
$6
Sector Perform
Maintained
7 Nov 2024
Barclays
Manav Patnaik
61% 1-year accuracy
25 / 41 met price target
25%downside
$4
Underweight
Maintained
7 Nov 2024

Financial journalist opinion

Based on 5 articles about CLVT published over the past 30 days

Positive
Zacks Investment Research
5 days ago
Does Clarivate (CLVT) Have the Potential to Rally 29.13% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 29.1% in Clarivate (CLVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Clarivate (CLVT) Have the Potential to Rally 29.13% as Wall Street Analysts Expect?
Neutral
PRNewsWire
5 days ago
BioWorld by Clarivate Releases Comprehensive 2024 Year in Review
Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON , Jan. 16, 2025 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review series. This multipart special report offers an in-depth analysis of the therapeutic trends, regulatory actions and economic shifts that defined biopharma, med tech and scientific innovation over the past year while forecasting key developments for 2025.
BioWorld by Clarivate Releases Comprehensive 2024 Year in Review
Neutral
GlobeNewsWire
1 week ago
Post-marketing Pharmacovigilance and Medical Information Market Research 2024: Rising Adverse Drug Reactions (ADRs) and Expanding Use of Biologics and Specialty Drugs Fueling Growth - Forecast to 2034
Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Post-marketing Pharmacovigilance and Medical Information Market by Type by Service, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering. The global post-marketing pharmacovigilance and medical information market size was estimated to be USD 6.22 billion in 2023 and is expected to reach USD 16.99 billion by 2034 with a CAGR of 9.56% during the forecast period 2024-2034.
Post-marketing Pharmacovigilance and Medical Information Market Research 2024: Rising Adverse Drug Reactions (ADRs) and Expanding Use of Biologics and Specialty Drugs Fueling Growth - Forecast to 2034
Neutral
PRNewsWire
1 week ago
Clarivate Launches DRG Fusion - A New Life Sciences Analytics Product Powered by Real-World Data
New modular analytics solution empowers commercial teams to optimize strategies and improve patient outcomes LONDON , Jan. 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of DRG Fusion, an innovative platform to support commercial analytics in life sciences. Powered by integrated real-world data and built by clinical and data science experts, Fusion provides biopharma and medtech organizations with the tools to understand and act in varied disease and competitive landscapes — eliminating the complexities of raw data management.
Clarivate Launches DRG Fusion - A New Life Sciences Analytics Product Powered by Real-World Data
Neutral
PRNewsWire
1 week ago
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON , Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to redefine the future of healthcare. This year, the highly anticipated resource highlights 11 drugs projected to achieve blockbuster status or revolutionize treatment paradigms within five years.
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Neutral
PRNewsWire
1 month ago
Clarivate Announces New $500 Million Share Repurchase Authorization
LONDON , Dec. 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today announced that its Board of Directors (the "Board") authorized a new share repurchase program of up to $500 million of the Company's outstanding ordinary shares through open-market purchases for a period of two years, from January 1, 2025 through December 31, 2026. The new share repurchase program replaces the current share repurchase program which terminates December 31, 2024, under which the Company repurchased $300 million of ordinary shares, including $200 million during the third and fourth quarters of 2024.
Clarivate Announces New $500 Million Share Repurchase Authorization
Neutral
PRNewsWire
1 month ago
Clarivate Launches AI-Powered Patent Search Solution in Derwent
Faster and more relevant results to empower critical IP decision-making LONDON , Dec. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of AI Search in Derwent™. Combining artificial intelligence (AI) with the premier source of global patent data, Derwent World Patents Index (DWPI)™, this solution will enable intellectual property (IP) professionals to make reliable innovation decisions by finding more relevant patents in less time.
Clarivate Launches AI-Powered Patent Search Solution in Derwent
Positive
MarketBeat
1 month ago
Bargains Galore? 3 Stocks With Insider Buying in the Millions
It's widely believed that insiders know how well a company is operating. Therefore, when insiders are actively buying their stock, it is assumed they must know something that's motivating them to buy shares.
Bargains Galore? 3 Stocks With Insider Buying in the Millions
Neutral
PRNewsWire
1 month ago
Clarivate and the Chinese Academy of Sciences Release Annual Collaborative Report to Identify 125 Research Fronts
Revealing highly active specialties in sciences and social sciences LONDON , Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, and the Chinese Academy of Sciences (CAS) today released 2024 Research Fronts™, identifying the most dynamic and rapidly growing specialties in sciences and social sciences. This marks the eleventh annual collaboration between the two organizations, with the report launched at a ceremony held in Beijing today.
Clarivate and the Chinese Academy of Sciences Release Annual Collaborative Report to Identify 125 Research Fronts
Neutral
PRNewsWire
1 month ago
Daikin Selects IPfolio from Clarivate
Enhancing operational efficiency for leading air conditioner manufacturer LONDON , Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Daikin Industries, Ltd. (Daikin) has selected IPfolio™ from Clarivate.
Daikin Selects IPfolio from Clarivate
Charts implemented using Lightweight Charts™